Clinical trials: Non-emergent Percutaneous Coronary Intervention (PCI)
Percutaneous Coronary Intervention
Safety and Efficacy of Enoxaparin in Percutaneous Coronary Intervention (PCI) Patients, an International Randomized Evaluation (STEEPLE)
The purpose of this study is to evaluate the efficacy and safety of intravenous enoxaparin versus intravenous unfractionated heparin (UFH) in patients undergoing non-emergent PCI, as assessed by measuring the incidence of…
- Trial name
- NCT00077844
- Testing
- Enoxaparin sodium
- Volunteers
- 3,532 people
- Sponsor
- Sanofi
High-risk Percutaneous Coronary Intervention
Magenta Elevate™ EFS in High-Risk PCI Patients
The Elevate™ EFS study is designed to evaluate the safety and feasibility of the Magenta Elevate™ percutaneous Left Ventricular Assist Device (pLVAD) System in patients undergoing non-emergent, high-risk percutaneous coronary…
- Trial name
- NCT05727059
- Testing
- The Elevate™ System
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Magenta Medical Ltd.
Arterial Obstructive Diseases, Coronary Disease
Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (Study P03573)
The object of the study is to determine whether different doses of SCH 530348, when added to standard medical care in persons undergoing percutaneous coronary intervention, will increase the risk of bleeding.
- Trial name
- NCT00132912
- Testing
- SCH 530348
- Volunteers
- 1,030 people
- Sponsor
- Merck Sharp & Dohme LLC
Arterial Occlusive Diseases, Coronary Artery Disease
Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention
The object of the study is to determine whether different doses of PZ-128, when added to standard medical care in persons undergoing cardiac catheterization/percutaneous coronary intervention, will increase the risk of bleeding.
- Conditions
- Arterial Occlusive Diseases, Coronary Artery Disease, Coronary Disease, Arteriosclerosis
- Trial name
- TRIP-PCI (NCT02561000)
- Testing
- PZ-128
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Tufts Medical Center
Acute Coronary Syndrome, Coronary Atherosclerosis
Routine Versus Selective Use of FFR to Guide PCI
Fractional flow reserve (FFR) is a test that can be performed at the time of heart catheterization. It measures the change in pressure across a narrowing in the heart artery during high flow situation, and provides reliable…
- Conditions
- Acute Coronary Syndrome, Coronary Atherosclerosis, Angina, Unstable
- Trial name
- FFR-SELECT (NCT02000661)
- Testing
- Fractional Flow Reserve (FFR)
- Where
- 4 sites in Canada
- Volunteers
- 261 people
- Sponsor
- Cardiology Research UBC
Non-emergent Percutaneous Coronary Intervention (PCI)
Transforming PCI Informed Consent Into an Evidence-based Decision-making Tool
Using individualized patient estimates of procedural risks and benefits, this project will transform the process of informed consent for coronary angioplasty into a dynamic educational tool for patients and physicians and is a…
- Trial name
- PRISM (NCT01383382)
- Where
- 7 sites in United States
- Volunteers
- 1,399 people
- Sponsor
- Saint Luke's Health System
High-Risk Percutaneous Coronary Intervention
Magenta Elevate™ First-in-Human Clinical Study in High-Risk PCI Patients
The Elevate™ First-In-Human (FIH) study is designed to evaluate the initial safety and device functionality of the Elevate™ percutaneous Left Ventricular Assist Device (pLVAD) System in patients undergoing non-emergent, high-risk…
- Trial name
- ELEVATE I (NCT06099548)
- Testing
- The Elevate™ System
- Where
- 2 sites in Georgia
- Volunteers
- 20 people
- Sponsor
- Magenta Medical Ltd.